Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;149(7):3371-3381.
doi: 10.1007/s00432-022-04220-w. Epub 2022 Aug 8.

Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort

Manuel Neuberger  1 , Nora Goly  2 , Janina Skladny  2 , Veronica Milczynski  2 , Christel Weiß  3 , Frederik Wessels  2 , Katja Nitschke  2 , Britta Grüne  2 , Caelán M Haney  4 , Friedrich Hartung  2 , Jonas Herrmann  2 , Jonas Jarczyk  2 , Karl F Kowalewski  2 , Frank Waldbillig  2 , Maximilian C Kriegmair  2 , Niklas Westhoff  2 , Thomas S Worst  2 , Philipp Nuhn  2
Affiliations

Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort

Manuel Neuberger et al. J Cancer Res Clin Oncol. 2023 Jul.

Abstract

Purpose: Advances in therapy of metastatic castration-refractory prostate cancer (mCRPC) resulted in more therapeutic options and led to a higher need of predictive/prognostic biomarkers. Systemic inflammatory biomarkers could provide the basis for personalized treatment selection. This study aimed to assess the modified Glasgow Prognostic Score (mGPS), the neutrophile-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR) and the systemic immune-inflammation index (SII) in men with mCRPC under docetaxel.

Methods: Patients with mCRPC and taxane chemotherapy at a tertiary care centre between 2010 and 2019 were screened retrospectively. The biomarkers mGPS, NLR, PLR and SII were assessed and analyzed for biochemical/radiologic response and survival.

Results: We included 118 patients. Of these, 73 (61.9%) had received docetaxel as first-line, 31 (26.2%) as second-line and 14 (11.9%) as third-line treatment. For biochemical response, mGPS (odds ratio (OR) 0.54, p = 0.04) and PLR (OR 0.63, p = 0.04) were independent predictors in multivariable analysis. SII was significant in first-line cohort only (OR 0.29, p = 0.02). No inflammatory marker was predictive for radiologic response. In multivariable analysis, mGPS and NLR (hazard ratio (HR) 1.71 and 1.12, both p < 0.01) showed significant association with OS in total cohort and mGPS in the first-line cohort (HR 2.23, p < 0.01). Haemoglobin (Hb) and alkaline phosphatase (AP) showed several significant associations regarding 1 year, 3 year, OS and biochemical/radiologic response.

Conclusions: Pre-treatment mGPS seems a promising prognostic biomarker. A combination of mGPS, NLR and further routine markers (e.g., Hb and AP) could yield optimized stratification for treatment selection. Further prospective and multicentric assessment is needed.

Keywords: Biomarker; Metastatic castration-refractory prostate cancer; Pre-treatment; Prognosis; Systemic inflammatory markers.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant financial or non-financial interests to disclose.

Figures

Fig. 1
Fig. 1
Flow-diagram and docetaxel treatment information of study cohort
Fig. 2
Fig. 2
Kaplan–Meier analysis of overall survival (OS) [months] depending on A mGPS in the total cohort B mGPS in the docetaxel first-line subgroup C NLR in the total cohort and D NLR in the docetaxel first-line subgroup
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cancer Stat Facts: Prostate Cancer. Retrieved 06.11.2021, from https://seer.cancer.gov/statfacts/html/prost.html.
    1. Ando K, Sakamoto S, Saito S, Maimaiti M, Imamura Y, Sazuka T, Sato N, Komiya A, Anzai N, Ichikawa T (2021) Prognostic value of high-sensitivity modified Glasgow prognostic score in castration-resistant prostate cancer patients who received docetaxel. Cancers 13(4):773 - PMC - PubMed
    1. Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M (2010) Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 16(1):203–211 - PubMed
    1. Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, der Kwast THV, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, der Poel HGV, Rouvière O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Mottet N (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 79(2):263–282 - PubMed
    1. Dolan RD, Laird BJA, Horgan PG, McMillan DC (2018) The prognostic value of the systemic inflammatory response in randomised clinical trials in cancer: a systematic review. Crit Rev Oncol Hematol 132:130–137 - PubMed

LinkOut - more resources